Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oregovomab and Nivolumab in Recurrent Ovarian Cancer
NCT03100006Phase 2Terminated
- Sponsor
- National Cancer Centre Singapore
- Start
- Feb 2017
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of oregovomab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Centre Singapore. Started Feb 2017; status: terminated.
02
Drugs
oregovomab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03100006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100006.